- Home
- BST vs NUVB Comparison
BST vs NUVB Comparison
Compare BST & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BST | NUVB |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | BST | NUVB |
|---|---|---|
| Price | $46.43 | $6.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 73.3K | ★ 6.4M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | N/A | $58.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.87 | $2.18 |
| 52 Week High | $51.30 | $9.75 |
Technical Indicators
Market Signals| Indicator | BST | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 61.31 |
| Support Level | $44.32 | $5.28 |
| Resistance Level | $46.35 | $8.95 |
| Average True Range (ATR) | 0.89 | 0.37 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 56.46 | 83.16 |
Price Performance
Historical ComparisonAbout BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.